2021 VCP Scientific Conference
Proudly supported by
Speakers
Booths
Cure VCP Disease, Inc.
Conference Sponsor
AllStripes
Conference Sponsor
Everylife Foundation for Rare Diseases
Conference Sponsor
Coordination of Rare Diseases at Sanford (CoRDS)
Industry Partner
Healx
Industry Partner
Po-Lin Chiu, PhD
Structural and functional analyses of disease-linked p97 ATPase mutant
Stephanie Moon, PhD
Coupling of translation quality control and mRNA targeting to stress granules
Alyaa Shmara, MBChB
High Prevalence of Frontotemporal Dementia in Females in Five Hispanic Families with R159H VCP Multisystem Proteinopathy
Alyaa Shmara, MBChB
A Clinicopathologic Study of Malignancy in VCP-Associated Multisystem Proteinopathy
Cheng Cheng, PhD
VCP/p97 inhibitor CB-5083 modulates muscle pathology in a mouse model of VCP inclusion body myopathy
Rod Carlo Columbres
Bone density studies using DEXA in patients with VCP myopathy and/or Paget disease of bone
Rod Carlo Columbres
Analysis of quantitative MRI features and functional assessment in IBMPFD patients
Rod Carlo Columbres
Semi-quantitative MRI and functional analysis of thigh muscles in IBMPFD patients
Jacob Klickstein
Modeling p97 ALS using isogenic IPSC-derived motor neurons
Feng Wang, PhD
p97/VCP ATPase inhibitors can prevent p97 mutation-linked motor neuron degeneration
Veronica Ferrari
Insight in VCP mutants pathological mechanisms: disruption of lysosomal stability, multilamellar bodies formation and autophagy activation
Jiang Zhu
Loss of Valosin-Containing Protein (VCP) activity enhances proteopathic seeding
Eiman Abdoalsadig
Utilization of CoRDS Registry to Monitor Quality of Life in Patients with VCP Disease
Manisha Korb, MD
Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy
Carly Pontifex
Examining Interactions Between Autophagy and Stress Granules Dysfunction in a Digenic VCP and TIA1 Distal Inclusion Body Myopathy
Rakesh Ganji, PhD
Regulation of ER-mitochondrial Contact Sites by the p97 AAA-ATPase
Natalie Reash, PT, DPT
Establishing clinical trial readiness for valosin containing protein-associated multisystem proteinopathy: baseline demographics from a 1-year prospective study
Mallory Jones
Overview of Valosin Containing Protein from the Perspective of a Rare Disease Advocacy Organization
Ankita Basu
CRISPR/Cas9-engineered Drosophila knock-in models to study VCP diseases
Brittany Ahlstedt
Regulation of ER-protein homeostasis by the p97-UBXN1 complex
Purbasha Nandi
Structural insights into the p97 disease mutant complex with p47 and its functional implications
Eileen Lynch, PhD
Effects of VCP mutations on endolysosomal damage and TDP-43 aggregation in skeletal muscle and neurons
Katelyn Green, PhD
Mechanisms of stress granule dysregulation caused by VCP mutations
Brenna Powers, PT, DPT
Evaluating consistency of subject performance between 2-day visits in subjects with valosin-containing protein multisystem proteinopathy
Megan Iammarino, PT, DPT
Utility and reliability of patient-reported outcome measures for valosin containing protein-associated multisystem proteinopathy: baseline results from a 1-year prospective study
Ryan Mahoney
Benefits of Remote Inspiratory Exercise Training in Familial Myopathy
Marianela Schiava, MD
Clinical classification of variants in the valosin containing protein gene associated with multisystem proteinopathy
Marianela Schiava, MD
Genotype-phenotype correlations in Valosin Containing Protein disease: Results of an International Multicentric study